Education
About Us
Working with TipRanks
Follow Us
Novavax (DE:NVV1)
BERLIN:NVV1
NVV1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€3.60 - €23.93
Previous CloseN/A
Volume7.16K
Average Volume (3M)58.00
Market Cap
$1.04B
Enterprise Value€618.06M
Total Cash (Recent Filing)$14.57M
Total Debt (Recent Filing)$460.00K
Price to Earnings (P/E)―
Beta2.43
Next Earnings
May 07, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding160,844,200
10 Day Avg. Volume1
30 Day Avg. Volume58
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.79
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.29
Enterprise Value/Ebitda-5.72
Forecast
1Y Price Target
€13.62Price Target Upside103.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNovavax reported 4Q24 revenue that exceeded Street consensus estimates, reflecting positively on the company's financial performance.
PartnershipsThe company signed a co-exclusive licensing agreement with global vaccine maker Sanofi, potentially bringing significant payments to Novavax.
Pipeline DevelopmentNovavax's combination vaccine candidates for influenza and COVID-19 have been granted Fast Track designation in the U.S., enhancing their potential market entry and acceptance.
Bears Say
Financial DependencyNovavax's potential reliance on milestone payments and strategic partnerships indicates a dependence on external factors for financial success.
Investor SentimentThe biggest hurdle to increased investor interest in Novavax is forgetting the company's complex past, including challenges such as selling a vaccine with shelf-life problems.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.40% Insiders
12.51%
Mutual Funds
17.82% Other Institutional Investors
51.69% Public Companies and
Individual Investors
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €3.60 and its highest was €23.93 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.04B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is May 07, 2025 which is in 35 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Feb 27, 2025. The company reported -€0.474 earnings per share for the quarter, beating the consensus estimate of -€0.477 by €0.004.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.39.
How many shares outstanding does Novavax have?
Novavax has 160,844,200 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -€0.474 in its last earnings report, beating expectations of -€0.477. Following the earnings report the stock price went up 2.802%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in DE:NVV1
---
Novavax Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.62 (103.53% Upside)
€13.62 (103.53% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 84%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $119.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
46.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.62%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
---
NVV1 Company Deck
---
NVV1 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights several positive strategic moves by Novavax, including a significant partnership with Sanofi, financial improvements, and new pipeline initiatives. However, these are counterbalanced by challenges such as declining revenues, dependence on Sanofi for future success, and regulatory uncertainties.Read More>---
NVV1 Stock 12 Month Forecast
Average Price Target
€13.62
▲(103.53% Upside)
Technical Analysis
Best Analysts Covering NVV1
1 Year
1 Year Success Rate
14/32 ratings generated profit
1 Year Average Return
+95.87%
reiterated a buy rating last month
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +95.87% per trade.
---